专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

WO2007080124A1 COMBINATION OF MTOR INHIBITOR AND ANTIPOLATE COMPOUND 审中-公开
标题翻译： MTOR抑制剂和抗静电复合物的组合
公开(公告)号：WO2007080124A1
公开(公告)日：2007-07-19
申请号：PCT/EP2007/000273
申请日：2007-01-12
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , LANE, Heidi , O'REILLY, Terence
发明人： LANE, Heidi , O'REILLY, Terence
IPC分类号： A61K31/519 , A61K31/436 , A61P35/00 , A61P17/06
CPC分类号： A61K45/06 , A61K31/436 , A61K31/519 , A61K2300/00
摘要： Use of a combination of an mTOR inhibitor and an antifolate compound.
摘要翻译：使用mTOR抑制剂和抗叶酸化合物的组合。

42. 发明申请

WO2007050655A3 COMBINATION OF HISTONE DEACETYLASE INHIBITORS AND RADIATION 审中-公开
标题翻译：组蛋白去乙酰化酶抑制剂和辐射
公开(公告)号：WO2007050655A3
公开(公告)日：2007-07-12
申请号：PCT/US2006041567
申请日：2006-10-23
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , VERSACE RICHARD WILLIAM
发明人： VERSACE RICHARD WILLIAM
IPC分类号： A61K31/165
CPC分类号： A61K31/165
摘要： This invention relates to organic compounds of formula (I): in particular, to pharmaceutical compositions for use in combination with ionizing radiation for the delay of progression or treatment of a proliferative disease, especially a solid tumor disease.
摘要翻译：本发明涉及式（I）的有机化合物：具体涉及与电离辐射组合用于延缓增殖性疾病，特别是实体瘤疾病的进展或治疗的药物组合物。

43. 发明申请

WO2007071443A1 INHIBITORS OF CCR9 ACTIVITY 审中-公开
标题翻译： CCR9活性抑制剂
公开(公告)号：WO2007071443A1
公开(公告)日：2007-06-28
申请号：PCT/EP2006/012476
申请日：2006-12-22
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CARBALLIDO HERRERA, José, M. , JAKSCHE, Herbert , LEHR, Philipp , WERNER, Gudrun , WINISKI, Anthony
发明人： CARBALLIDO HERRERA, José, M. , JAKSCHE, Herbert , LEHR, Philipp , WERNER, Gudrun , WINISKI, Anthony
IPC分类号： C07C311/21 , C07C311/29 , A61K31/18 , A61P1/00
CPC分类号： C07C311/21 , C07C311/29 , C07C2601/14 , C07C2603/74
摘要： Compounds of formula (I), in which R 1 and R 2 are independently a substituted phenyl group, where the substituents are as defined in the claims and with the proviso that at least one of the substituents is a cyano, carboxy or (C 1-4 )alkoxycarbonyl group, are inhibitors of CCR9 activity useful for therapeutic treatment, particularly of irritable bowel disease.
摘要翻译：式（I）化合物，其中R 1和R 2各自独立地是取代的苯基，其中取代基如权利要求中所定义，条件是在至少一个取代基是氰基，羧基或（C 1-4 - ）烷氧基羰基，是可用于治疗性治疗，特别是肠易激综合征的CCR9活性的抑制剂。

44. 发明申请

WO2007067615A3 THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS 审中-公开
公开(公告)号：WO2007067615A3
公开(公告)日：2007-06-14
申请号：PCT/US2006/046545
申请日：2006-12-06
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , BARNES, David , BEBERNITZ, Gregory Raymond , COPPOLA, Gary Mark , NAKAJIMA, Katsumasa , STAMS, Travis , TOPIOL, Sidney Wolf , VEDANANDA, Thalaththani Ralalage , WAREING, James Richard
发明人： BARNES, David , BEBERNITZ, Gregory Raymond , COPPOLA, Gary Mark , NAKAJIMA, Katsumasa , STAMS, Travis , TOPIOL, Sidney Wolf , VEDANANDA, Thalaththani Ralalage , WAREING, James Richard
IPC分类号： C07D285/10 , C07D417/04 , C07D417/10 , A61K31/433 , A61P3/10
摘要： Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer (such as prostate or breast cancer), osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

45. 发明申请

WO2007064407A1 TRANSDERMAL THERAPEUTIC SYSTEM 审中-公开
标题翻译：变态治疗系统
公开(公告)号：WO2007064407A1
公开(公告)日：2007-06-07
申请号：PCT/US2006/039557
申请日：2006-10-10
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , LTS LOHMANN THERAPIE-SYSTEME AG , GARGIULO, Paul, M. , LANE, Roger, Michael , PLATT, Beatrix , THEOBALD, Frank , WALL, Bettina
发明人： GARGIULO, Paul, M. , LANE, Roger, Michael , PLATT, Beatrix , THEOBALD, Frank , WALL, Bettina
IPC分类号： A61K9/70 , A61K31/27
CPC分类号： A61K9/7084 , A61K9/7061 , A61K31/27
摘要： The present invention relates to Transdermal Therapeutic Systems having a silicone adhesive layer, to Transdermal Therapeutic Systems providing specific plasma concentrations, to their manufacture and use.
摘要翻译：本发明涉及具有硅氧烷粘合剂层，提供特定血浆浓度的透皮治疗系统的透皮治疗系统，用于其制造和使用。

46. 发明申请

WO2007062805A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS 审中-公开
标题翻译： 3-（取代的氨基） - 吡唑并[3,4-d]嘧啶作为EPHB和VEGFR2激酶抑制剂
公开(公告)号：WO2007062805A1
公开(公告)日：2007-06-07
申请号：PCT/EP2006/011416
申请日：2006-11-28
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , HOLZER, Philipp , IMBACH, Patricia , FURET, Pascal , SCHMIEDEBERG, Niko
发明人： HOLZER, Philipp , IMBACH, Patricia , FURET, Pascal , SCHMIEDEBERG, Niko
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00
CPC分类号： C07D487/04
摘要： The invention relates to novel pyrazolo[3,4-d]pyrimidines of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
摘要翻译：本发明涉及下式的新型吡唑并[3,4-d]嘧啶，其中所有变量如说明书中所定义，以游离形式或盐形式，其制备方法，用作药物和药物包括他们。

47. 发明申请

WO2007045420A3 3-ALKYL-5- (4-ALKYL-5-OXO-TETRAHYDROFUTRAN-2-YL) PYRROLIDIN-2-ONE DERIVATIVES AS INTERMEDIATES IN THE SYNTHESIS OF RENIN INHIBITORS 审中-公开
标题翻译： 3-烯丙基-5-（4-烷基-5-氧代四氢呋喃-2-基）吡咯烷-2-酮衍生物作为合成RININ抑制剂的中间体
公开(公告)号：WO2007045420A3
公开(公告)日：2007-06-07
申请号：PCT/EP2006009970
申请日：2006-10-16
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , SEDELMEIER GOTTFRIED , GRIMLER DOMINIQUE , ACEMOGLU MURAT
发明人： SEDELMEIER GOTTFRIED , GRIMLER DOMINIQUE , ACEMOGLU MURAT
IPC分类号： C07D405/04 , C07D207/26 , C07D307/32 , C07D307/33 , C07F1/02
CPC分类号： C07D405/04 , C07C271/22 , C07D207/26 , C07D307/33 , Y02P20/55
摘要： The invention related to a novel process, novel process steps and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially renin inhibitors, such as Aliskiren. Inter alia, the invention relates to a process for the manufacture of a compound of the formula II, or a salt thereof, and a compound of formula Vl or a salt thereof, wherein R 3 and R 4 as well as Act are as defined in the specification, and processes of manufacturing these. Additionally transformation of compounds (Vl) with metallo organic compounds (VII) give rise to the new compounds (VMI) which are direct precursors for the preparation of Aliskiren.
摘要翻译：本发明涉及可用于合成药物活性化合物，特别是如阿利吉仑的肾素抑制剂的新方法，新方法步骤和新型中间体。特别地，本发明涉及制备式II化合物或其盐，式VI化合物或其盐的方法，其中R 3和R 4 > 4 以及Act如规范中所定义，以及制造这些的过程。化合物（VI）与金属有机化合物（VII）的另外转化产生作为制备阿利吉仑的直接前体的新化合物（VMI）。

48. 发明申请

WO2007015870A3 CRYSTALLINE FORMS OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE 审中-公开
标题翻译： 4-甲基-N- [3-（4-甲基咪唑-1-基）-5-三氟甲基苯基] -3-（4-吡啶-3-基 - 吡咯烷-2-基）氨基]苯甲酰胺的结晶形式
公开(公告)号：WO2007015870A3
公开(公告)日：2007-06-07
申请号：PCT/US2006027875
申请日：2006-07-18
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , MANLEY PAUL W , SHIEH WEN-CHUNG , SUTTON PAUL ALLEN , KARPINSKI PIOTR H , WU RAEANN , MONNIER STEPHANIE , BROZIO JOERG
发明人： MANLEY PAUL W , SHIEH WEN-CHUNG , SUTTON PAUL ALLEN , KARPINSKI PIOTR H , WU RAEANN , MONNIER STEPHANIE , BROZIO JOERG
IPC分类号： C07D401/14 , A61K31/506 , A61P35/00
CPC分类号： C07D401/14
摘要： Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes.
摘要翻译： 4-甲基-N- [3-（4-甲基 - 咪唑-1-基）-5-三氟甲基 - 苯基] -3-（4-吡啶-3-基 - 嘧啶-2-基氨基） - 苯甲酰胺的结晶形式游离碱及其盐通过各种方法制备。

49. 发明申请

WO2007058992A2 MUTATIONS AND POLYMORPHISMS OF HDAC6 审中-公开
标题翻译： HDAC6的突变和多态性
公开(公告)号：WO2007058992A2
公开(公告)日：2007-05-24
申请号：PCT/US2006/043899
申请日：2006-11-13
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
IPC分类号： A61K48/00 , A61K31/00 , C12N15/63 , A61P35/00
CPC分类号： A61K31/00 , A61K38/15 , A61K48/00 , C12Q1/6886
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the HDAC6 gene. The invention provides new HDAC6 mutations and SNPs5 useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the HDAC6 mutations of the invention, expression vectors encoding the HDAC6 mutant polypeptides of the invention and organisms that express the HDAC6 mutant and polymorphic ' polynucleotides and/or HDAC6 mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the HDAC6 mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析测试，并且更具体地涉及HDAC6基因的遗传多态性和突变的方面。本发明提供了用于诊断和治疗有需要的受试者的新的HDAC6突变和SNP5。因此，本发明的各个方面涉及编码本发明的HDAC6突变的多核苷酸，编码本发明HDAC6突变多肽的表达载体和表达HDAC6突变体和多态性'多核苷酸和/或HDAC6突变体/多态性多肽的有机体本发明。本发明的各个方面还涉及使用本发明的HDAC6突变和多态性鉴定易患疾病的个体或将个体分类为药物反应性，副作用或最佳药物剂量的诊断/诊断方法和试剂盒。

50. 发明申请

WO2007058991A2 MUTATIONS AND POLYMORPHISMS OF C-ABL 审中-公开
标题翻译： C-ABL的突变和多态性
公开(公告)号：WO2007058991A2
公开(公告)日：2007-05-24
申请号：PCT/US2006/043898
申请日：2006-11-13
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
发明人： CULVER, Kenneth, Wayne , ZHU, Jian , LILLEBERG, Stan
IPC分类号： A61K48/00 , C12Q1/68 , A61P35/00 , A61K31/00 , C12N15/63
CPC分类号： A61K31/00 , C12N9/1205
摘要： This invention relates generally to the analytical testing of tissue samples in vitro, and more particularly to aspects of genetic polymorphisms and mutations of the c ABL gene. The invention provides new c ABL mutations and SNPs, useful in the diagnosis and treatment of subjects in need thereof. Accordingly, the various aspects of the present invention relate to polynucleotides encoding the c ABL mutations of the invention, expression vectors encoding the c ABL mutant polypeptides of the invention and organisms that express the c ABL mutant and polymorphic polynucleotides and/or c ABL mutant/polymorphic polypeptides of the invention. The various aspects of the present invention further relate to diagnostic/theranostic methods and kits that use the c ABL mutations and polymorphisms of the invention to identify individuals predisposed to disease or to classify individuals with regard to drug responsiveness, side effects, or optimal drug dose.
摘要翻译：本发明一般涉及体外组织样品的分析测试，并且更具体地涉及c ABL基因的遗传多态性和突变的方面。本发明提供了用于诊断和治疗有需要的受试者的新的cABL突变和SNP。因此，本发明的各个方面涉及编码本发明的cABL突变的多核苷酸，编码本发明的cABL突变体多肽的表达载体和表达cABL突变体和多态性多核苷酸和/或cABL突变体/ 本发明的多态性多肽。本发明的各个方面还涉及诊断/诊断方法和试剂盒，其使用本发明的cABL突变和多态性来鉴定易患疾病的个体或关于药物响应性，副作用或最佳药物剂量对个体进行分类

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式